A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

2026-525234-39-00 · tracked via the Priya Life Science EU tracker

Sponsor

Janssen Cilag International

Sponsor type

Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

13/07/2026

Enrollment target

175

Sites

France, Spain, Germany, Denmark, Belgium

Condition studied

Relapsed or Refractory acute myeloid leukemia, Relapsed or Refractory chronic lymphocytic leukemia, Relapsed or Refractory higher-risk myelodysplastic syndromes, Relapsed or Refractory small lymphocytic lymphoma

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525234-39-00 on CTIS ↗ ← All trials in the EU